PURIST Trademark
Trademark Overview
On Thursday, December 22, 2022, a trademark application was filed for PURIST with the United States Patent and Trademark Office. The USPTO has given the PURIST trademark a serial number of 97728407. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, June 4, 2024. This trademark is owned by GENECENTRIC THERAPEUTICS, INC.. The PURIST trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Assays for the medical diagnostic, prognostic and predictive testing of tumors; diagnostic preparations for medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays for testing tissue samples; biological preparations for the detection, diagnosis, subtyping and monitoring of cancer
Medical testing services for diagnosis, prognosis, treatment, and management of cancer; Medical testing for diagnostic and treatment option purposes; Providing molecular genetics and genomics testing and reporting services in the field of biomarkers for the diagnosis, prognosis, treatment or management of cancer; Provision of health care services, namely, providing oncological testing reports to physicians
Providing medical and scientific research in the field of oncology, tumor biology, and diagnosis and treatment of cancers; Pharmaceutical research services; Providing medical research and scientific research information in the field of oncology; Providing medical and scientific research services in the field of cancer diagnosis, prognosis, therapy, prevention, treatment and patient management; Providing research and development services in the field of oncology; Research and development in the field of RNA expression, namely, cancer biology; Research and development services for others, namely, research and development of assays for oncological testing and diagnostic purposes; Scientific research in the field of RNA expression analysis and reporting; Providing laboratory research services in the field of pancreatic cancer; Research and development in the fields of biomarker discovery and validation; Medical and scientific research in the field of biomarker discovery in cancer patients;...
General Information
| Serial Number | 97728407 |
| Word Mark | PURIST |
| Filing Date | Thursday, December 22, 2022 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, June 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 9, 2024 |
Trademark Statements
| Goods and Services | Assays for the medical diagnostic, prognostic and predictive testing of tumors; diagnostic preparations for medical purposes; medical diagnostic reagents; medical diagnostic reagents and assays for testing tissue samples; biological preparations for the detection, diagnosis, subtyping and monitoring of cancer |
| Goods and Services | Medical testing services for diagnosis, prognosis, treatment, and management of cancer; Medical testing for diagnostic and treatment option purposes; Providing molecular genetics and genomics testing and reporting services in the field of biomarkers for the diagnosis, prognosis, treatment or management of cancer; Provision of health care services, namely, providing oncological testing reports to physicians |
| Goods and Services | Providing medical and scientific research in the field of oncology, tumor biology, and diagnosis and treatment of cancers; Pharmaceutical research services; Providing medical research and scientific research information in the field of oncology; Providing medical and scientific research services in the field of cancer diagnosis, prognosis, therapy, prevention, treatment and patient management; Providing research and development services in the field of oncology; Research and development in the field of RNA expression, namely, cancer biology; Research and development services for others, namely, research and development of assays for oncological testing and diagnostic purposes; Scientific research in the field of RNA expression analysis and reporting; Providing laboratory research services in the field of pancreatic cancer; Research and development in the fields of biomarker discovery and validation; Medical and scientific research in the field of biomarker discovery in cancer patients; Pharmaceutical and medical research in the field of survival outcomes and standard of care research; Medical research featuring the identification and validation of cancer related biomarkers and RNA expression for use in improved patient outcomes; Providing a website and information in the field of medical research and scientific research in the fields of tumor biology, oncology, and diagnosis and treatment of cancers; |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, January 19, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | GENECENTRIC THERAPEUTICS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Durham, NC 27713 |
| Party Name | GENECENTRIC THERAPEUTICS, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Durham, NC 27713 |
Trademark Events
| Event Date | Event Description |
| Monday, December 26, 2022 | NEW APPLICATION ENTERED |
| Thursday, January 19, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, September 22, 2023 | ASSIGNED TO EXAMINER |
| Friday, September 22, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, September 22, 2023 | NON-FINAL ACTION E-MAILED |
| Friday, September 22, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, December 19, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Friday, March 1, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, March 1, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 4, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 20, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 9, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 19, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, March 1, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 9, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 10, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, June 4, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, October 1, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, October 1, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, October 1, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
